Equibles does not estimate personal net worth.
Get an email with a short summary when Atea Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AVIR alertsThe proxy statement of Atea Pharmaceuticals, Inc. reports total compensation of $1,217,738 for John Vavricka in fiscal 2025, including a base salary of $443,169. Disclosed compensation is on record for 5 fiscal years. John Vavricka has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for Atea Pharmaceuticals, Inc. on September 15, 2026. Atea Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Atea Pharmaceuticals, Inc. includes Jean-Pierre Sommadossi (CEO and Board Member), Andrea Corcoran (CFO), Wayne Foster (Chief Accounting Officer) and 7 others.
“So right now we haven't released anything on pricing, but we plan to be competitive within the pricing regimen. closely matching to what the two competitors currently are.”
“HCV remains a significant global healthcare crisis, with an increasing incidence of infections, despite the availability of direct vaccine virals for the past decade.”
Proxy statement
Start not stated–present
Last confirmed April 27, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Commercial Officer | $443,169 | $1,217,738 |
| 2024 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Commercial Officer | $430,261 | $1,386,663 |
| 2023 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Commercial Officer | $417,729 | $1,515,658 |
| 2022 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Commercial Officer | $397,838 | $1,522,843 |
| 2021 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Commercial Officer | $386,250 | $6,599,415 |
